Advice
Following a full submission
Conjugated oestrogen 0.3mg, medroxyprogesterone 1.5mg (Premique Low Dose) is accepted for use within NHS Scotland as hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women with an intact uterus.
It is effective in controlling vasomotor symptoms and is associated with lower rates of breast pain and endometrial bleeding compared to other products with higher oestrogen content. It is more expensive than several other HRT therapies, but less expensive than the current market leader in Scotland.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- Conjugated oestrogen medroxyprogesterone (Premique Low Dose®)
- SMC ID:
- 130/04
- Indication:
- Hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women with an intact uterus
- Pharmaceutical company
- Wyeth Pharmaceuticals
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 November 2004